ciprofloxacin

(redirected from Cipro xr)
Also found in: Dictionary, Medical, Wikipedia.
Related to Cipro xr: ciprofloxacin, Ciproxin
  • noun

Synonyms for ciprofloxacin

an oral antibiotic (trade name Cipro) used against serious bacterial infections of the skin or respiratory tract or urinary tract or bones or joints

Synonyms

References in periodicals archive ?
At study entry, more than half of the patients reported a decreased amount of time spent at work or in other activities, which was reduced to 22 percent of patients at 24 hours upon taking Cipro XR, and 10 percent at 48 hours after having taken the drug.
In this study, Cipro XR was shown to provide fast symptom relief, enabling participants' to quickly return to their normal routines.
You can view full prescribing information for Cipro XR at http://www.
S Food and Drug Administration just approved Cipro XR, a once-daily version of Cipro Tablets, for the treatment of uncomplicated UTIs.
The once-a-day convenience of Cipro XR may contribute to compliance among patients, thereby helping to reduce the risk of UTI relapse and subsequent resistant infection," said Dr.
The study enrolled 1,042 patients and compared 1000mg once-daily Cipro XR to a twice-daily 500 mg dose of conventional Cipro(R) (ciprofloxacin HCl).
The prospective, randomized, double-blind, North American multicenter clinical trial included 435 patients (343 with cUTI and 92 with AUP) and compared 1000mg once-daily Cipro XR to a twice-daily 500 mg dose of conventional Cipro.
For cUTI and AUP combined, bacteriological eradication (evaluated 5 to 11 days post-therapy) was achieved in 89 percent of patients treated with once-daily Cipro XR and 85 percent of patients treated with conventional twice-daily Cipro.
Cipro XR will be marketed for use at a dosage strength of 500 mg.
Cipro XR was developed using a bilayer matrix of the active ingredient ciprofloxacin, and enables two different release mechanisms.
We developed Cipro XR in direct response to the needs of our customers.
Food and Drug Administration (FDA) in March 2002 to market Cipro XR for the treatment of uncomplicated UTI in the once daily tablet formulation used in this trial.
This NDA submission for Cipro XR in complicated urinary tract infections represents Bayer's commitment to developing and bringing to market innovative therapies," said Dr.